Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hememics Biotechnologies Inc. has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner, SUN, CAITLYN MINGYUN. The prosecution is restricted to 1 distinct art unit, indicating a narrow technical focus for the company's active chemistry filings. This concentration within a single art unit can lead to a more specialized examination of the biotechnology-related chemistry claims.
The busiest examiner, SUN, CAITLYN MINGYUN, manages 1 pending office action. Given that there is only 1 distinct examiner and 1 pending action, the company's current prosecution efforts are entirely concentrated. This provides a singular point of interaction for the company's chemistry intellectual property at the patent office. The busiest examiner pending figure of 1 confirms that the company's current prosecution strategy is entirely centered on the feedback from this specific individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SUN, CAITLYN MINGYUN | 1 | 63.7% | +11.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17925548 | MULTIPLEX BIOSENSOR FOR RAPID POINT-OF-CARE DIAGNOSTICS | SUN, CAITLYN MINGYUN | 60d overdue |
| Art Unit | Apps |
|---|---|
| 1795 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17925548 | MULTIPLEX BIOSENSOR FOR RAPID POINT-OF-CARE DIAGNOSTICS | SUN, CAITLYN MINGYUN | 1795 | §103 | Final Rejection | 60d overdue | Pending | Nov 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHememics Biotechnologies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Caitlyn Mingyun Sun has the most, with 1 of Hememics Biotechnologies Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
